FORETELL MY HEALTH

Based in South Korea, FORETELL MY HEALTH specializes in advanced diagnostic technologies for early detection of ovarian and endometrial cancers, utilizing innovative AI-powered algorithms and platelet-derived RNA analysis. FORETELL MY HEALTH, founded in 2022 and headquartered in Pohang-si, South Korea, focuses on developing technologies for cancer diagnostics. The company's CEO, Taeh-jin Ahn, leads a team that has completed a total of 3 deals, with their most recent transaction dated July 2, 2025, when they secured funding from Nextdream Angelclub. FORETELL MY HEALTH specializes in advanced diagnostic technologies aimed at the early detection of ovarian and endometrial cancers.

The company's core product leverages platelet-derived RNA analysis and a proprietary AI-powered algorithm to identify cancerous indicators at an early stage. This approach provides a more accessible, efficient, and accurate means of cancer screening compared to traditional methods. Their target clientele includes healthcare providers, hospitals, and laboratories in South Korea, with an emphasis on enhancing patient outcomes through timely interventions. They plan to expand their offerings globally, promoting their diagnostic capabilities in markets that prioritize early cancer detection.

FORETELL MY HEALTH's revenue model is based on partnerships with healthcare institutions and service contracts that facilitate the implementation of their diagnostic technology. Collaborations with hospitals and clinics integrate the company's testing services into their oncology departments. They provide comprehensive screening packages for healthcare providers, with pricing structures determined by the volume of tests ordered and contractual agreements made with each partner. While individual pricing details remain undisclosed, the company emphasizes effective and innovative cancer detection solutions for the medical community.

FORETELL MY HEALTH plans to utilize their recent funding from July 2025 to enhance their product line, specifically with upcoming launches in advanced diagnostic tools aimed at improving cancer detection. They are targeting expansion into new markets, particularly focusing on regions in Southeast Asia and Europe by 2027, to reach a wider audience in need of early cancer detection solutions.